Sevabertinib Makes HER2 Testing Actionable in NSCLC
FDA granted accelerated approval to sevabertinib for advanced nonsquamous NSCLC with activating HER2 kinase-domain mutations, emphasizing accurate biomarker identification and FDA-authorized diagnostic testing for eligibility.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.